SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer

Figure 3 Prognostic value of p53/SPARCL1 model in colorectal cancer patients. According to the prediction result (PR) given by the p53/SPARCL1 model, patients could be divided into two groups: “high risk” (PR > 0) and “low risk” (PR < 0). A: 3-year survival of the “low risk” group was 88.30%, significantly higher at twice that of the “high risk” group, which was only 37.84% (P < 0.001). B: The 3-year survival of stage II (n = 43) and III (n = 56) patients was 88.40% vs 62.50% (P = 0.039), with an only 15.90% survival difference (P = 0.039); C: The same 99 stage II/III patients, when divided by the PR of the p53/SPARCL1 model: the 3-year survival of “low risk” (n = 70) and “high risk” (n = 29) group was 87.14% vs 37.93%, with a survival difference of 49.21% (P < 0.001), much more than the difference between stage II and III patients; D: According to the PR of the p53/SPARCL1 model, the 3-year survival of “low risk” and “high risk” patients at stage II was 100% and 54.55%, respectively, with a significant difference of 45.45% (P < 0.001); E: At stage III (n = 56), the 3-year survival was 78.95% of “low risk” patients and 27.78% of “high risk” patients, with a 51.17% higher survival rate (P < 0.001); F: At stage III (n = 56), the 3-year survival was different between stage IIIA/IIIB (n = 34) and IIIC (n = 22) patients: 82.36% vs 31.82% (P < 0.001).